Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 7/20 | 0.56 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894096 | 0.80 | PLA2G2A (0.56) | PLA2G2ASERPINE1PPARDTHRBPDE4A | |
| SCHEMBL3203412 | 0.80 | SERPINE1 (0.64) | PLA2G2ASERPINE1PPARD | |
| SCHEMBL3858076 | 0.79 | SERPINE1 (0.85) | SERPINE1THRBPDE4APDE4BPDE4C | |
| SCHEMBL4937574 | 0.79 | SERPINE1 (0.83) | SERPINE1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7679573 | 0.78 | SERPINE1 (0.59) | PLA2G2ASERPINE1PPARDTHRB | |
| SCHEMBL6699599 | 0.74 | IDO1 (0.57) | PLA2G2ASERPINE1THRBPDE4APDE4B | |
| SCHEMBL13178070 | 0.73 | TP53 (0.56) | SERPINE1THRBPDE4APDE4BPDE4C | |
| SCHEMBL2156832 | 0.72 | PLA2G2A (1.00) | PLA2G2ASERPINE1 | |
| SCHEMBL5893957 | 0.72 | PDE4A (0.75) | PLA2G2ASERPINE1PPARDPDE4APDE4B | |
| SCHEMBL28512821 | 0.72 | LMNA (0.57) | PLA2G2ASERPINE1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | claimed |
| EP-1569901-B1 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | claimed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2004-07-15 | — | — | US | claimed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1569901-B1 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052854-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | PLA2G2A 1905/4885SERPINE1 1/4885PPARD 2366/4885 |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, PLAT, SERPINC1 | PLA2G2A 1523/4885SERPINE1 1/4885PPARD 752/4885 |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, SERPINC1, PLAT | PLA2G2A 1548/4885SERPINE1 1/4885PPARD 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.